Japan Pharmas Seeing Lowest Stock Prices In Industry History
This article was originally published in PharmAsia News
Executive Summary
Japanese pharmaceutical companies are experiencing some of the lowest stock values in the history of the industry, led by Takeda Pharmaceutical and Astellas Pharma in share-price plunges. The Japan drop is sharing the fate of U.S. and European competitors as drug makers face government cutbacks in medical expenses and patents expire for some key products. Pharmas in developed countries are beginning to focus their attention more on emerging markets where incomes are increasing, but Japanese pharmas trail in that switch. (Click here for more - a subscription may be required
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.